Paclitaxel and Radiation Therapy in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer

NCT ID: NCT00647218

Last Updated: 2017-02-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 38 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2000-02-29
• Study Completion Date: 2004-11-30

Brief Summary

RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving paclitaxel and radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery.

PURPOSE: This clinical trial is studying how well giving paclitaxel together with radiation therapy works in treating patients undergoing surgery for stage II or stage III breast cancer.

Detailed Description

OBJECTIVES:

Primary

• Evaluate the efficacy of paclitaxel and concurrent radiotherapy (as measured by pathologic response rates) in patients with stage II or III breast cancer.

Secondary

• Evaluate the toxicities of this treatment regimen.
• Correlate paclitaxel-induced tumor response with local recurrence-free survival, distant disease-free survival, and overall survival.
• Evaluate protein expression profiles by mass spectrometry in biopsy material and blood specimens collected before and after treatment with paclitaxel.

OUTLINE:

• Neoadjuvant chemotherapy: Patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.
• Chemoradiotherapy: Beginning 3-4 weeks after completion of neoadjuvant chemotherapy, patients receive paclitaxel IV over 1 hour twice weekly and undergo radiotherapy once daily, 5 days a week, for 6½ weeks.
• Surgery: At 6-8 weeks after completion of chemoradiotherapy, patients undergo surgical resection (e.g., modified radical mastectomy or lumpectomy and axillary node dissection).
• Adjuvant chemotherapy: Beginning 4-6 weeks after surgery, patients receive doxorubicin hydrochloride IV over 20 minutes and cyclophosphamide IV over 1 hour on day 1. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
• Hormonal therapy: After completion of adjuvant chemotherapy, patients with estrogen receptor- and/or progesterone receptor-positive tumor receive hormonal therapy at the discretion of the treating physician.

Patients undergo blood and tissue sample collection periodically to analyze changes in cell cycle by flow cytometry; antibody assays; kinase assays for cyclin B1/CDC2; genetic assays for p53, p21, and other molecular markers; and protein expression assays by mass spectrometry.

After completion of study therapy, patients are followed periodically.

Conditions

Breast Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Experimental

Group Type: EXPERIMENTAL

Post-operative adjuvant therapy

Intervention Type: DRUG

Adriamycin 60 mg/m2 IV over 20 minutes and Cytoxan 600 mg/m2 IV over 1 hour will be given every three weeks for 4 cycles.

neoadjuvant therapy

Intervention Type: DRUG

Paclitaxel 175 mg/m2 IV every 3 weeks x 3 cycles

therapeutic surgical procedure

Intervention Type: PROCEDURE

Modified radical mastectomy or segmental mastectomy plus axillary dissection 6-8 weeks following completion of chemotherapy/Radiotherapy.

Radiation therapy with concurrent Paclitaxel

Intervention Type: RADIATION

Radiation to breast 4680 cGy/26 fractions with concurrent Paclitaxel 30 mg/m2, twice per week

Hormonal Therapy

Intervention Type: DRUG

After completion of postoperative adjuvant Adriamycin and Cytoxan, hormonal therapy should be given at the discretion of the treating physician for all post-menopausal ER and/or PR positive patients. It is also recommended for pre-menopausal patients who are ER and/or PR positive.

Interventions

Post-operative adjuvant therapy

Adriamycin 60 mg/m2 IV over 20 minutes and Cytoxan 600 mg/m2 IV over 1 hour will be given every three weeks for 4 cycles.

Intervention Type: DRUG

neoadjuvant therapy

Paclitaxel 175 mg/m2 IV every 3 weeks x 3 cycles

Intervention Type: DRUG

therapeutic surgical procedure

Modified radical mastectomy or segmental mastectomy plus axillary dissection 6-8 weeks following completion of chemotherapy/Radiotherapy.

Intervention Type: PROCEDURE

Radiation therapy with concurrent Paclitaxel

Radiation to breast 4680 cGy/26 fractions with concurrent Paclitaxel 30 mg/m2, twice per week

Intervention Type: RADIATION

Hormonal Therapy

After completion of postoperative adjuvant Adriamycin and Cytoxan, hormonal therapy should be given at the discretion of the treating physician for all post-menopausal ER and/or PR positive patients. It is also recommended for pre-menopausal patients who are ER and/or PR positive.

Intervention Type: DRUG

Other Intervention Names

None noted; None noted; None noted; None noted

Eligibility Criteria

Inclusion Criteria

DISEASE CHARACTERISTICS:

• Histologically or cytologically documented invasive carcinoma of the breast*

• Tumor ≥ 2 cm in greatest dimension (e.g., T2-4) and any nodal status (e.g., N0-3), including locally advanced disease, as defined by the following criteria:

• Primary tumor ≥ 5 cm
• Tumor of any size with direct extension to the chest wall or skin
• Inflammatory breast cancer (T4d)
• Metastasis to ipsilateral internal mammary node
• Ipsilateral lymph nodes that are clinically fixed to each other or to other structures (N2) NOTE: *Diagnosis may be made by core or tru-cut biopsies
• Measurable or evaluable tumor

• Measurable disease is defined as any mass that can be reproducibly measured in two perpendicular dimensions
• Evaluable disease is defined as any lesion visible by mammogram or palpable by physical exam that does not fit the above criteria of measurability
• Planning to undergo breast conservation surgery
• Willing to undergo AND is a candidate for radiotherapy, in the judgement of the treating radiation oncologist
• No evidence of distant metastatic disease (e.g., lung, liver, bone, brain)
• Hormone receptor status not specified

PATIENT CHARACTERISTICS:

• Menopausal status not specified
• ECOG performance status 0-1
• WBC ≥ 3,000/mm^3
• Platelet count ≥ 100,000/mm^3
• Creatinine ≤ 1.5 times upper limit of normal (ULN)
• Bilirubin ≤ 1.5 times ULN
• Left ventricular ejection fraction ≥ 45%
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No other malignancies within the past 5 years, except curatively treated nonmelanomatous skin cancer or carcinoma in situ of the cervix
• No history of hypersensitivity reaction to products containing polysorbate 80 (Tween 80)
• No serious medical illness that, in the judgment of the treating physician, places the patient at risk
• No peripheral neuropathy ≥ grade 2

PRIOR CONCURRENT THERAPY:

• Prior tamoxifen as chemoprevention allowed
• No prior radiotherapy to the ipsilateral breast

• Prior radiotherapy to the contralateral breast is allowed
• No prior chemotherapy

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

Vanderbilt-Ingram Cancer Center

OTHER

Sponsor Role: lead

Responsible Party

A Bapsi Chakravarthy, MD

Associate Professor; Radiation Oncologist

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

A. Bapsi Chakravarthy, MD

Role: STUDY_CHAIR

Vanderbilt-Ingram Cancer Center

Locations

Williamson Medical Center

Frankling, Tennessee, United States

Jackson-Madison Hospital

Jackson, Tennessee, United States

Boston Baskin Cancer Center

Memphis, Tennessee, United States

Methodist Lebonheur Healthcare

Memphis, Tennessee, United States

Meharry Medical College

Nashville, Tennessee, United States

Vanderbilt-Ingram Cancer Cetner

Nashville, Tennessee, United States

Countries

United States

Other Identifiers

P30CA068485

Identifier Type: NIH

Identifier Source: secondary_id

View Link

VU-VICC-BRE-9936

Identifier Type: -

Identifier Source: secondary_id

VCC BRE 9936

Identifier Type: -

Identifier Source: org_study_id